Pharmafile Logo

pertuzumab

- PMLiVE

Novartis’ Kisqali shows long-term improvements in breast cancer patients

Data shows the ‘longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients’

- PMLiVE

Wilmington Healthcare appoints new Solutions Director

Kirsty Fryer has been promoted to the role of Solutions Director for Wilmington Healthcare

Wilmington Healthcare

Roche Basel Switzerland

EC approves Venclyxto-based combinations for newly diagnosed AML

The treatment is approved for newly diagnosed acute myeloid leukaemia patients who can’t receive intensive chemotherapy

Roche Basel Switzerland

Roche’s Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients

Interim results from the phase 3 study to be presented at ASCO 2021

- PMLiVE

NICE recommends Ultomiris for NHS use in patients with rare blood disorders

aHUS is an ultra-rare and life-threatening disease that causes progressive injury to vital organs

Understanding the role of provider collaboratives

Oli Hudson, Content Director at Wilmington Healthcare, takes a look at the new groups of providers that are expected to play a pivotal role in integrating care.

Wilmington Healthcare

- PMLiVE

Detailed results for Regeneron’s antibody cocktail continue to show benefit in high-risk COVID-19 outpatients

Treatment shortened symptom duration and reduced viral load in non-hospitalised patients with COVID-19

- PMLiVE

NICE recommends Keytruda for colorectal cancer patients with rare mutations

Approximately 450 patients in England will now become eligible for this treatment on the NHS

- PMLiVE

Prothena achieves $60m milestone as part of Roche collaboration

Milestone reached as first patient doses in phase 2b trial of prasinezumab in early Parkinson's disease patients

- PMLiVE

Novartis announces delay in UK cholesterol drug study

The delay was caused by recruitment issues during the COVID-19 pandemic

Roche Basel Switzerland

Roche reports strong diagnostics sales in Q1 as demand for COVID-19 tests continues

Company continues to report a significant impact of biosimilar competition on established brands

- PMLiVE

NICE sets out plans for ‘ambitious’ five-year strategy

NICE refocuses on reducing health inequalities and accelerating access to the latest and most effective treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links